Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neuren Pharmaceuticals Limited ( (AU:NEU) ) just unveiled an update.
Neuren Pharmaceuticals reported a significant increase in profit after tax for H1 2025, driven by increased royalty income from DAYBUE, a treatment for Rett syndrome. The company completed a A$50 million share buyback and retains strong cash reserves, enabling the advancement of its NNZ-2591 drug pipeline for multiple neurological conditions. Key developments include FDA Fast Track designation for NNZ-2591 in Pitt Hopkins syndrome and the initiation of a Phase 3 trial for Phelan-McDermid syndrome. The company’s strategic initiatives and financial strength position it for future growth in both the US and international markets.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$22.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is a biopharmaceutical company focused on developing therapies for neurodevelopmental disorders and other neurological conditions. Its primary products include DAYBUE (trofinetide) for Rett syndrome, and NNZ-2591 for various neurological disorders. The company is actively involved in expanding its market presence through strategic partnerships and development programs.
Average Trading Volume: 496,304
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$2.23B
Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.